US OptionsDetailed Quotes

CCCC241018P4000

Watchlist
  • 0.55
  • 0.000.00%
15min DelayClose Sep 9 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

News

Comments

    Jaguar8
    Jaguar8
    Sep 8 17:05
    NEWS
    $C4 Therapeutics (CCCC.US)$
    C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
    C4 Therapeutics (Nasdaq: CCCC) announced the release of an abstract containing clinical data from its ongoing Phase 1 trial of CFT1946, a novel BiDAC™ degrader, for mutant BRAF V600 solid tumors.
    The abstract, with a data cut-off of April 12, 2024, is available on the ESMO Congress 2024 website. An oral presentation sch...
    Jaguar8
    Jaguar8
    Jul 16 15:05
    NEWS
    $C4 Therapeutics (CCCC.US)$
    C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
    C4 Therapeutics (Nasdaq: CCCC) has announced that preliminary data from the monotherapy dose escalation portion of their ongoing Phase 1/2 clinical trial of CFT1946 will be presented at the ESMO Congress 2024 in Barcelona, Spain. CFT1946 is a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors. The present...
    Jaguar8
    Jaguar8
    Apr 29 15:03
    $C4 Therapeutics (CCCC.US)$
    NEWS
    C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    C4 Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant includes non-qualified stock options to purchase 146,880 shares of common stock, with the options vesting over a four-year period. This grant was approved by the Company's Board of Directors and serves as an inducement for the employee to join C4 Therapeutics.
    Pushkyy
    Pushkyy
    Mar 13 08:44
    $C4 Therapeutics (CCCC.US)$ doesnt look like its gonna go up by much ..
    Trytosaveabit
    Trytosaveabit
    Mar 4 06:06
    News
    $C4 Therapeutics (CCCC.US)$ C4 Therapeutics Has Entered Into A License Agreement With Merck KGaA, To Exclusively Discover Two Targeted Protein Degraders Against Critical Oncogenic Proteins, C4 Therapeutics Will Receive $16M As Upfront And Is Eligible Of Up $740M In Milestone Payment
Read more